28067119|t|Efficacy and safety of " unboosting " atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF
28067119|a|To assess safety and efficacy of a switch to unboosted atazanavir (ATV) among HIV-infected adults receiving ATV / ritonavir (r) and tenofovir disoproxil fumarate (TDF). HIV-infected adults with viral load (VL) <40 copies/mL at screening and <150 copies/mL consistently for ≥3 months while receiving a regimen including ATV /r and TDF were randomized to continue ATV / r 300/100 mg daily (control) or change to ATV 400 mg daily (switch), while maintaining their TDF backbone. The primary outcome was proportion of subjects without treatment failure (regimen switch or VL > 200 copies/mL twice consecutively) at 48 weeks. Fifty participants (46 male, median age 47 years) were randomized, 25 to each arm. At week 48, treatment success occurred in 76% in the control arm and 92% in the switch arm (ITT, p = 0.25). ATV trough levels at week 9 were higher in controls (median 438 ng/mL) than in the switch arm (median 124 ng/mL) (p = 0.003), as was total bilirubin at week 48 (median 38 μmol/L and 28 μmol/L, respectively; p = 0.02). Estimated glomerular filtration rate (eGFR) decreased in the control arm (p = 0.007), but did not change in the switch arm. At week 48, eGFR was higher in the switch arm (median 96 mL/min) than in the control arm (median 85 mL/min) (p = 0.035), but the arms were similar with respect to fasting glucose, C-reactive protein, and lipid parameters. Switching from ATV / r to unboosted ATV appears to be safe and effective in selected virologically suppressed patients receiving TDF -containing regimens, and may have favorable effects on bilirubin and renal function.
28067119	0	8	Efficacy	T062	UMLS:C1707887
28067119	13	19	safety	T062	UMLS:C1705187
28067119	38	48	atazanavir	T103	UMLS:C1145759
28067119	54	81	randomized controlled trial	T062	UMLS:C0206035
28067119	88	100	HIV-infected	T038	UMLS:C0019693
28067119	120	132	tenofovir DF	T103	UMLS:C1099776
28067119	188	198	atazanavir	T103	UMLS:C1145759
28067119	200	203	ATV	T103	UMLS:C1145759
28067119	211	223	HIV-infected	T038	UMLS:C0019693
28067119	241	244	ATV	T103	UMLS:C1145759
28067119	247	256	ritonavir	T103	UMLS:C0292818
28067119	258	259	r	T103	UMLS:C0292818
28067119	265	294	tenofovir disoproxil fumarate	T103	UMLS:C1099776
28067119	296	299	TDF	T103	UMLS:C1099776
28067119	302	314	HIV-infected	T038	UMLS:C0019693
28067119	327	337	viral load	T058	UMLS:C1168369
28067119	339	341	VL	T058	UMLS:C1168369
28067119	360	369	screening	T058	UMLS:C0220908
28067119	434	441	regimen	T058	UMLS:C0040808
28067119	452	455	ATV	T103	UMLS:C1145759
28067119	463	466	TDF	T103	UMLS:C1099776
28067119	472	482	randomized	T062	UMLS:C0034656
28067119	495	498	ATV	T103	UMLS:C1145759
28067119	501	502	r	T103	UMLS:C0292818
28067119	543	546	ATV	T103	UMLS:C1145759
28067119	594	597	TDF	T103	UMLS:C1099776
28067119	646	654	subjects	T098	UMLS:C0080105
28067119	663	680	treatment failure	T033	UMLS:C0162643
28067119	682	689	regimen	T058	UMLS:C0040808
28067119	759	771	participants	T098	UMLS:C0679646
28067119	808	818	randomized	T062	UMLS:C0034656
28067119	944	947	ATV	T103	UMLS:C1145759
28067119	997	1003	median	T082	UMLS:C0549183
28067119	1039	1045	median	T082	UMLS:C0549183
28067119	1083	1092	bilirubin	T103	UMLS:C0005437
28067119	1105	1111	median	T082	UMLS:C0549183
28067119	1162	1198	Estimated glomerular filtration rate	T058	UMLS:C3811844
28067119	1200	1204	eGFR	T058	UMLS:C3811844
28067119	1256	1266	not change	T033	UMLS:C0442739
28067119	1298	1302	eGFR	T058	UMLS:C3811844
28067119	1333	1339	median	T082	UMLS:C0549183
28067119	1376	1382	median	T082	UMLS:C0549183
28067119	1449	1464	fasting glucose	T058	UMLS:C0202045
28067119	1466	1484	C-reactive protein	T103	UMLS:C0006560
28067119	1490	1495	lipid	T103	UMLS:C0023779
28067119	1523	1526	ATV	T103	UMLS:C1145759
28067119	1529	1530	r	T103	UMLS:C0292818
28067119	1544	1547	ATV	T103	UMLS:C1145759
28067119	1637	1640	TDF	T103	UMLS:C1099776
28067119	1653	1661	regimens	T058	UMLS:C0040808
28067119	1697	1706	bilirubin	T103	UMLS:C0005437
28067119	1711	1725	renal function	T038	UMLS:C0232804